Yahoo Finance • last month
Cohort 2 fully enrolled; enrollment and dosing now underway for Cohort 3 (final dose level); No cases of amyloid-related imaging abnormalities (ARIA) observed to date; The trial, expected to enroll 128 patients, remains on track to repor... Full story
Yahoo Finance • 2 months ago
* ProMIS Neurosciences press release [https://seekingalpha.com/pr/20199117-promis-neurosciences-announces-second-quarter-2025-financial-results-and-corporate-highlights] (NASDAQ:PMN [https://seekingalpha.com/symbol/PMN]): Q2 GAAP EPS of... Full story
Yahoo Finance • 2 months ago
TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 28, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic antibodies targeting... Full story
Yahoo Finance • 3 months ago
* ProMIS Neurosciences (NASDAQ:PMN [https://seekingalpha.com/symbol/PMN]) has raised [https://seekingalpha.com/pr/20172913-promis-neurosciences-announces-0_8-million-registered-direct-offering-priced-at-the-market]$0.8 million at-the-mar... Full story
Yahoo Finance • 3 months ago
ProMIS Neurosciences Inc. (NASDAQ:PMN) announced Monday it has mutually agreed with BTIG, LLC to terminate its At The Market Offering Agreement, effective immediately. The agreement, originally established on January 5, 2024, allowed the c... Full story
Yahoo Finance • 3 months ago
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Opendoor Technologies Inc. 343,720,987 3.38 2.615 3.2042 +0.9542 TNF Pha... Full story
Yahoo Finance • 7 months ago
CAMBRIDGE, Massachusetts , March 13, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic... Full story
Yahoo Finance • 7 months ago
CAMBRIDGE, Massachusetts, March 11, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded pr... Full story
Yahoo Finance • 8 months ago
CAMBRIDGE, Massachusetts, Jan. 29, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded pro... Full story
Yahoo Finance • 2 years ago
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Nov. 20, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolde... Full story
Yahoo Finance • 2 years ago
Raised $20.4 million in PIPE gross proceeds to support continued development of Company’s PMN310 and novel antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases Dosing of first subjects in first-in-human P... Full story
Yahoo Finance • 2 years ago
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Sept. 08, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the generation and development of antibody therapeu... Full story
Yahoo Finance • 2 years ago
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Sept. 06, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfold... Full story
Yahoo Finance • 2 years ago
At-the-Market Fundraise supports Company through several potentially value-creating milestones and beyond TORONTO, Ontario and CAMBRIDGE, Massachusetts, Aug. 21, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS... Full story
Yahoo Finance • 2 years ago
Presented compelling preclinical data supportingtherapeutic potential of PMN310 to treat Alzheimer’s disease,and the promise of disease prevention with acomputationally derived Alzheimer’s disease vaccine candidate atAAIC 2023 TORONTO, On... Full story
Yahoo Finance • 2 years ago
TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 14, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (NASDAQ: PMN) (“ProMIS” or the “Corporation”) is pleased to announce that it has completed its continuance (the “Contin... Full story
Yahoo Finance • 2 years ago
Company to voluntarily delist from the Toronto Stock Exchange (TSX)Last trading day on TSX will be July 21, 2023 TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 10, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasd... Full story
Yahoo Finance • 2 years ago
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 30, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (NASDAQ: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting tox... Full story
Yahoo Finance • 2 years ago
TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 29, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (NASDAQ: PMNRFXF) (“ProMIS” or the “Corporation”) is issuing this release to correct the URL required to virtually acce... Full story
Yahoo Finance • 2 years ago
Received FDA clearance for investigational new drug (IND) application for lead therapeutic candidate, PMN310, in Alzheimer’s diseasePresented preclinical data supporting target identification and candidate differentiation across pipeline o... Full story